Similar articles

• The numbers are in: statins for the primary prevention of cardiovascular disease in women.

  Duvernoy CS, Blumenthal R. Duvernoy CS, et al. Circulation. 2010 Mar 9;121(9):1063-5. doi: 10.1161/CIR.0b013e3181d731c6. Epub 2010 Feb 22. Circulation. 2010. PMID: 20176993 No abstract available.
• [Comment from the cardiologic viewpoint].

  Lüscher TF. Lüscher TF. Praxis (Bern 1994). 2009 Feb 4;98(3):129-30. doi: 10.1024/1661-8157.98.3.129. Praxis (Bern 1994). 2009. PMID: 19180438 German. No abstract available.
• [Comment from the family practice viewpoint].

  Coradi B. Coradi B. Praxis (Bern 1994). 2009 Feb 4;98(3):131. doi: 10.1024/1661-8157.98.3.131. Praxis (Bern 1994). 2009. PMID: 19180439 German. No abstract available.
• [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].

  Olsson AG. Olsson AG. Lakartidningen. 2009 May 20-Jun 2;106(21-22):1471-5. Lakartidningen. 2009. PMID: 19579435 Review. Swedish. No abstract available.
• Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

  Ridker PM; JUPITER Study Group. Ridker PM, et al. Circulation. 2003 Nov 11;108(19):2292-7. doi: 10.1161/01.CIR.0000100688.17280.E6. Circulation. 2003. PMID: 14609996 Review. No abstract available.